B. Riley Securities Initiates Coverage On Ambrx Biopharma with Buy Rating, Announces Price Target of $26
Portfolio Pulse from richadhand@benzinga.com
B. Riley Securities analyst Yuan Zhi initiates coverage on Ambrx Biopharma (NASDAQ:AMAM) with a Buy rating and announces a price target of $26.
June 14, 2023 | 10:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ambrx Biopharma (NASDAQ:AMAM) receives a Buy rating from B. Riley Securities with a price target of $26.
B. Riley Securities initiating coverage on Ambrx Biopharma with a Buy rating and a price target of $26 indicates a positive outlook for the stock. This news is likely to attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100